Accurate quantification of dystrophin mRNA and exon skipping levels in Duchenne Muscular Dystrophy

van Ommen, 2008, The therapeutic potential of antisense-mediated exon skipping, Curr Opin Mol Ther, 10, 140 Aartsma-Rus, 2009, Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations, Hum Mutat, 30, 293, 10.1002/humu.20918 van Deutekom, 2007, Local dystrophin restoration with antisense oligonucleotide PRO051, N Engl J Med, 357, 2677, 10.1056/NEJMoa073108 Kinali, 2009, Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study, Lancet Neurol, 8, 918, 10.1016/S1474-4422(09)70211-X Heemskerk, 2009, In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping, J Gene Med, 11, 257, 10.1002/jgm.1288 Arechavala-Gomeza, 2007, Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle, Hum Gene Ther, 18, 798, 10.1089/hum.2006.061 Yin, 2008, Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function, Hum Mol Genet, 17, 3909, 10.1093/hmg/ddn293 Ivanova, 2008, Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle, Nucleic Acids Res, 36, 6418, 10.1093/nar/gkn671 Lu, 2005, Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles, Proc Natl Acad Sci USA, 102, 198, 10.1073/pnas.0406700102 Doran, 2009, Proteomic profiling of antisense-induced exon skipping reveals reversal of pathobiochemical abnormalities in dystrophic mdx diaphragm, Proteomics, 9, 671, 10.1002/pmic.200800441 Denti, 2008, Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice, Hum Gene Ther, 19, 601, 10.1089/hum.2008.012 Wu, 2009, Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino, Gene Therapy, 17, 132, 10.1038/gt.2009.120 Reed, 2007, High-resolution DNA melting analysis for simple and efficient molecular diagnostics, Pharmacogenomics, 8, 597, 10.2217/14622416.8.6.597 Deligezer, 2007, A novel application of melting curves: utility of peak area calculation for relative methylation quantification, Clin Chem Lab Med, 45, 867, 10.1515/CCLM.2007.146 Zimmermann, 2008, Digital PCR: a powerful new tool for noninvasive prenatal diagnosis?, Prenat Diagn, 28, 1087, 10.1002/pd.2150 Vitiello, 2008, In vivo delivery of naked antisense oligos in aged mdx mice: analysis of dystrophin restoration in skeletal and cardiac muscle, Neuromuscul Disord, 18, 597, 10.1016/j.nmd.2008.05.011 Muir, 2009, Emerging strategies for cell and gene therapy of the muscular dystrophies, Expert Rev Mol Med, 11, e18, 10.1017/S1462399409001100 Wilton, 1999, Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides, Neuromuscul Disord, 9, 330, 10.1016/S0960-8966(99)00010-3 Bremmer-Bout, 2004, Targeted exon skipping in transgenic hDMD mice: a model for direct preclinical screening of human-specific antisense oligonucleotides, Mol Ther, 10, 232, 10.1016/j.ymthe.2004.05.031 Mortazavi, 2008, Mapping and quantifying mammalian transcriptomes by RNA-Seq, Nat Methods, 5, 621, 10.1038/nmeth.1226 Sommer, 1980, The size distributions of proteins, mRNA, and nuclear RNA, Mol Evol, 15, 37, 10.1007/BF01732582 Rimessi, 2009, Cationic PMMA nanoparticles bind and deliver antisense oligoribonucleotides allowing restoration of dystrophin expression in the mdx mouse, Mol Ther, 17, 820, 10.1038/mt.2009.8